LYFAQUIN

About Centhaquine (Lyfaquin® in India): Centhaquine is a frontline therapy used along with the standard of care and is well-positioned to a critical unmet need as a pharmacologically active resuscitative agent. A decrease in the volume of blood circulation from blood or fluid loss due to trauma, gastrointestinal bleeding, major surgery, postpartum hemorrhage, diarrhea, or vomiting can cause hypovolemic shock. About 1.9 million people worldwide die because of hemorrhagic shock every year, most dying within the first 6 hours. Centhaquine activates venous alpha2B adrenergic receptors to increase cardiac preload and activates central alpha2A adrenergic receptors to decrease cardiac afterload. Thereby, Centhaquine converts the venous unstressed blood volume to stressed blood volume and improves cardiac output and blood circulation, making it an ideal candidate for the resuscitation of patients with hypovolemic shock.
Centhaquine was approved in India by Drugs Controller General of India following a successful phase III clinical trial. The results of are published in a manuscript entitled “A Multicentric, Randomized, Controlled Ph III Study of Centhaquine (Lyfaquin®), as a Resuscitative Agent in Hypovolemic Shock Patients”.